Metabolic Dysfunction Associated Steatotic Liver Disease (MASLD) encompasses hepatic steatosis, steatohepatitis (MASH), and cirrhosis and is one of the two leading causes of liver transplantation globally. The recurrence and emergence of MASLD following transplantation is an increasing concern, with significant progression to fibrosis and cirrhosis widely documented. MASLD is linked to higher mortality rates due to cardiovascular disease, non-hepatic cancers, and graft cirrhosis. Early diagnosis through non-invasive fibrosis tests, alongside strategies to modify existing risk factors, is essential for management, as there is currently no optimal medical therapy available for post-transplant patients. Further research into the pathogenesis, natural progression, metabolic risk factors, and the impact of immunosuppressive medications on MASLD is needed to improve the management of post-transplant patients.